Guillain–Barré Variant as primary presentation of systemic lupus erythematosus and class V lupus nephritis

Guillain–Barré Variant as primary presentation of systemic lupus erythematosus and class V lupus nephritis

Saifat Ullah khan¹, MD. Muftah Othman, MD, FRCP. Zeeshan Nasir, MBBS. Syed Hidayat Ali, MBBS. Shahid Fazal, MBBS. Saeed Takish MBChB MSc, MRCP.

^1.Nephology Unit, Hazm mebaireek hospital,Qatar;  ^2.Hamad Medical Corporation, Doha, Qatar

Any organ of the body can be affected in systemic lupus erythematosus (SLE) which is an auto immune. Patients can present with clinical features of mild joint and skin involvement to life-threatening kidney, hematologic, or central nervous system involvement. Peripheral neuropathies in SLE is not an uncommon presentation but Guillain–Barré syndrome (GBS) is considered as an unusual and one of the least neuropsychiatric syndromes in SLE. In this case report we are aiming to report a rare association of GBS as an initial presentation for an SLE in a male patient. A 46-year-old male patient present with overlapping symptoms and required admission to intensive care unit. He was diagnosed initially as case of GBS treated with Intravenous immunoglobulin (IVIG) for five days with improvement. Patient developed overlapping symptoms of fever, palindromic polyarthralgia with active urine sediment, and proteinuria lead to diagnosis of class V lupus nephritis. Prednisolone and Mycophenolate mofetil given and he received rituximab injection for extra renal manifestation of SLE.

Keywords: Guillain–Barré syndrome (GBS), systemic lupus erythematosus, Lupus nephritis, Intravenous immunoglobulin (IVIG) Acute Inflammatory Demyelinating Polyradiculoneuropathy.

Free Full-text PDF

How to cite this article:

Saifat Ullah khan, Muftah Othman, Zeeshan Nasir, Syed Hidayat Ali, Shahid Fazal,Saeed Takish. Guillain–Barré Variant as primary presentation of systemic lupus erythematosus and class V lupus nephritis. International Journal of Case Reports, 2023, 7:289. DOI: 10.28933/ijcr-2023-02-2205skan

References:

1. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41:1714.
2. Ugarte-Gil MF, Gonzalez LA, Alarcon GS. Lupus: the new epidemic. Lupus. 2019;28(9):1031-50. doi: 10.1177/0961203319860907. [PubMed: 31299878].
3. Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:529.
4. Ahn GY, Kim D, Won S, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus 2018; 27:1338.
5. El Hadidi KT, Medhat BM, Abdel Baki NM, et al. Characteristics of systemic lupus erythematosus in a sample of the Egyptian population: a retrospective cohort of 1109 patients from a single center. Lupus 2018; 27:1030.
6. Unterman A, Nolte JE, Boaz M et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin. Arthritis. Rheum. (2011).
7. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018; 93:789.
8. Liang MH, Corzillius M, Bae SCet al.The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis. Rheum.42(4), 599–608(1999)
9. Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901.
10. Lahita RG. The clinical presentation of systemic lupus erythematosus. Syst. Lupus. Eryth. 525–539 (2011).
11. Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis 2020; 76:265.
12. Hanly JG, Urowitz MB, Su L, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69:529.
13. Hanly J, Urowitz M, Sanchez – Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis. Rheum. 56(1), 265–273 (2007).
14. Nadri Q, Althaf MM. Guillian-Barre syndrome as the initial presentation of systemic lupus erythematosus–case report and review of literature. Ann. Saud. Med. 35(3), 263–5 (2015).
15. Hanly JG, Urowitz MB, Gordon C, et al. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis 2020; 79:356.
16. Kuwabara S. Guillain-barré syndrome. Drugs. 64(6), 597–610 (2004).
17. Jasti AK, Selmi C, Sarmiento-Monroy JC et al. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment. Expert. Rev. Clin. Immunol. 12(11), 1175–1189 (2016).
18. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J. Infect Dis. 176(Supplement_2), S92–S8 (1997).
19. Ropper AH, Wijdicks EFM, Truax BT. In: Guillain-Barré Syndrome, Contemporary Neurology Series. Davis FA, editor. Vol. 34. Philadelphia, PA: 1991. Comp.
20. Okoh HC, Lubana SS, Langevin S et al. A case of systemic lupus erythematosus presenting as Guillain-Barré syndrome. Case. Reports. Rheumatol. 2015, (2015).